Tellgen / 透景生命
Shanghai ChiNext multiplex IVD OEM — tumor, infectious and autoimmune kits
About Tellgen / 透景生命
Founded in 2003 and headquartered in Shanghai's Zhangjiang Hi-Tech Park, Tellgen Corporation operates as a key player in the in-vitro diagnostics (IVD) market. The company, led by Chairman and General Manager Jian Er Yao, specializes in the research, development, manufacturing, and distribution of diagnostic products and instruments. Tellgen achieved a significant milestone in 2017 when it was listed on the Shenzhen stock market. The firm's initial public offering was reportedly 8,114.4 times oversubscribed, indicating strong market interest at the time of its debut.
The company's business model is centered on the sale of a comprehensive portfolio of IVD products. Its offerings cover a wide range of medical fields including tumor monitoring, autoimmune diseases, cardiovascular health, infectious diseases, and reproductive health. Tellgen has developed multiple technology platforms, such as flow fluorescence, chemiluminescence, multiplex PCR, and mass spectrometry to support its product lines. Key products include tumor markers, HPV testing kits, DNA methylation detection kits, and various autoimmune antibody panels. The company primarily serves hospitals and other healthcare institutions, with a strong presence in major Chinese cities and an expanding international footprint that began in 2020.
Strategically, Tellgen is focused on creating an integrated "Diagnosis + Therapy" ecosystem. This is evidenced by its recent exclusive strategic investment in CytoCares, an entity developing therapies for autoimmune diseases. Furthermore, the company has expanded its capabilities in molecular pathology through the acquisition of Wuhan HealthCare Biotechnology, a company specializing in fluorescence in situ hybridization (FISH) technology. These moves highlight a long-term strategy to extend from diagnostics into therapeutic innovation, aiming to provide full-cycle healthcare solutions.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2017
- Outcome tier
- Colt$25–100M revenue
News
Open roles
Tellgen / 透景生命 in its local ecosystem
The Tellgen / 透景生命 office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tellgen / 透景生命 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tellgen / 透景生命 on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



